Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × cixutumumab × Tumor-Agnostic × Clear all
NCT01007032 2019-02-27

A Study of IMC-A12 in Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
21 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00785538 2019-01-08

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
24 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡